

JUN 3 2005 3:58PM

AVENTIS US PAT DEPT

RECEIVED
CENTRAL FAX CENTER

NO. 5853 P. 1

JUN 03 2005


PTO/SB/21 (09-04)


Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/616,141	
	Filing Date	July 08, 2003	
	First Named Inventor	PAULS, et al.	
	Art Unit	1624	
	Examiner Name		
Total Number of Pages in This Submission	4	Attorney Docket Number	USA3676 US CNT

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	1. Request for Corrected Filing Receipt
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	2. Copy of the Updated Filing Receipt
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature			
Printed name	Julie Anne KNIGHT		
Date	June 3, 2005	Reg. No.	48,867

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. (USPTO FAX NO. 703-746-9195; Total No. of Pages Transmitted: 4)			
Signature			
Typed or printed name	Renee McGinnis	Date	June 3, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re Application of
PAULS, et al.****Examiner:****Application No.: 10/616,141****Art Unit: 1624****Filed: July 8, 2003****Title: 1-AROYL-PIPERIDINYL
BENZAMIDINES****TELEFAX CERTIFICATE**

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, Alexandria, VA 22313, on 703-746-9195

June 3, 2005
Date of Transmission
Renee McGinnis
Signature

REQUEST FOR CORRECTED FILING RECEIPT

Mail Stop Initial Patent Examination's Filing Receipt Corrections
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Attached is a copy of the Updated Filing Receipt from the Patent and Trademark Office in the
above-identified application, for which issuance of a corrected filing receipt is respectfully requested.

There is an error in the Foreign Application section. The correct date for the listed Foreign
Application should read as follows: "UNITED KINGDOM 0018306.1 07/26/2000", and not
"UNITED KINGDOM 0018306.1 07/27/2000".

Respectfully submitted,

June 3, 2005

Julie Anne Knight
Julie Anne Knight, Reg. No. 48,867
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
(member of the sanofi-aventis group)
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3679
Telefax (908) 231-2626

Aventis Docket No. USA3676 US CNT



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1459
 Alexandria, Virginia 22311-1459
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/616,141	07/08/2003	1624	1772	USA3676 US CNT		35	1

05487
 ROSS J. OEHLER
 AVENTIS PHARMACEUTICALS INC.
 ROUTE 202-206
 MAIL CODE: D303A
 BRIDGEWATER, NJ 08807

CONFIRMATION NO. 2919

UPDATED FILING RECEIPT

OC00000013343482

COMPUTER ENTERED
 7/29/04

Date Mailed: 07/28/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Heinz Pauls, Flemington, NJ;
 Yong Gong, Bridgewater, NJ;
 Julian Levell, Summit, NJ;
 Peter Astles, Kent, UNITED KINGDOM;
 Paul R. Eastwood, Essex, UNITED KINGDOM;

Assignment For Published Patent Application

AVENTIS PHARMACEUTICALS INC, Bridgewater, NJ;

Domestic Priority data as claimed by applicant

This application is a CON of 09/841,417 04/24/2001 ABN
 which claims benefit of 60/200,066 04/27/2000

Foreign Applications

UNITED KINGDOM 0018306.1 07/27/2000 *Correct date is 07/26/2000*

If Required, Foreign Filing License Granted: 10/03/2003

Projected Publication Date: 11/04/2004

Non-Publication Request: No



Early Publication Request: No

Title

1-Aroyl-piperidinyI benzamides

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).